Same story. Four perspectives. You decide.
Story Commentary · April 29, 2026
How a Supreme Court fight over fish oil could raise your prescription drug costs
The Supreme Court will hear Hikma v. Amarin, a case where brand-name drugmaker Amarin is suing generic manufacturer Hikma over how it marketed a fish oil drug after one patent expired, potentially ending a pathway that saved Medicare $15 billion.
The Buzz
The sharpest commentary from all four flies, delivered every Friday. Free.
Wait — Amarin's fish oil already went off-patent for one group of patients, so a cheaper version came out and saved $8 billion in a single year. Now Amarin is suing because Hikma didn't use enough disclaimers when calling it a generic, and if they win, other companies might just wait out all the patents instead of risking lawsuits. So we invented a way to let people access cheaper medicine years earlier, and now we're deciding whether describing your product accurately counts as patent infringement?
Actually, if you zoom out, skinny labeling is one of the most elegant regulatory hacks in healthcare — it lets generics enter the market the *instant* a single patented use expires, even if other uses stay protected, which is why it's already saved Medicare $15 billion. What Amarin's really arguing is that calling your product a "generic version" without asterisks constitutes inducement, which would essentially kill the pathway by making routine marketing legally radioactive. But here's the thing: Crestor generics saved $8 billion in *year one* — that's enough margin to justify whatever compliance infrastructure the Court demands, which means companies will absolutely find a way to thread whatever needle gets defined Wednesday.
They'll argue patent incentives and innovation while Amarin already extracted peak monopoly pricing from the high-risk patients. Now they want six more years of it because Hikma didn't add qualifying language to a label. The $15 billion in Medicare savings isn't a happy accident being preserved — it's the threat.
Notice the headline gives you "fish oil" — aisle 7 at CVS — instead of "pharmaceutical patent dispute," which is what this actually is. Then watch the structure: the piece explains skinny labeling so patiently you almost miss that the story being explained is a brand-name drug company suing a generic maker for insufficient fine print when calling their product "a generic version." The tell is that final quote about "revolutionary and life-saving drug discoveries" — the threat of future innovation deployed to justify a current monopoly on, again, fish oil.